MCOW - ETF AI Analysis
Top Page
Pacer S&P MidCap 400 Quality FCF Aristocrats ETF (MCOW)
MCOW, the Pacer S&P MidCap 400 Quality FCF Aristocrats ETF, has a solid overall rating driven mainly by high-quality mid-cap companies with strong financial performance and positive outlooks, such as Medpace, Exelixis, Qualys, and Rambus, which show robust profitability, cash generation, and growth potential. Some larger positions like Pure Storage and DocuSign add growth but are held back by bearish technical signals and high valuations, and several holdings share similar overvaluation or momentum concerns, making valuation risk and periods of technical weakness the main factors limiting the fund’s rating.
MCOW vs. SPDR S&P 500 ETF (SPY)
- AUM
- 1.12M
- Region
- North America
- Expense Ratio
- 0.49%
- Beta
- 0.94
- Issuer
- Pacer
- Inception Date
- Aug 27, 2025
- Dividend Yield
- 0.25%
- Asset Class
- Equity
- Index Tracked
- S&P MidCap 400 Quality FCF Aristocrats Index
MCOW Summary
MCOW is an ETF that follows the S&P MidCap 400 Quality FCF Aristocrats Index, focusing on mid-sized U.S. companies with strong, steady cash flows. It holds a mix of sectors, with a big tilt toward technology, and includes well-known names like DocuSign and Okta. Investors might consider MCOW if they want growth potential from mid-cap stocks while still aiming for companies that have shown financial strength over time. A key risk is that it is heavily exposed to mid-sized and tech-focused companies, so its price can swing more than the overall market.
How much will it cost me?
This ETF has an expense ratio of 0.49%, which means you’ll pay about $4.90 per year for every $1,000 invested. That’s higher than the average cost for broad, passively managed index ETFs because this fund tracks a more specialized index focused on mid-cap companies with strong, consistent free cash flow.
What would affect this ETF?
This ETF is heavily invested in U.S. mid-cap technology, industrial, and health care companies, so it could benefit if innovation, business spending, and demand for medical treatments stay strong and the economy grows steadily. On the other hand, it may be hurt by rising interest rates that pressure growth stocks like DocuSign and Okta, economic slowdowns that reduce corporate spending, or new regulations affecting tech and pharmaceutical firms in its top holdings.
MCOW Top 10 Holdings
MCOW is leaning heavily into U.S. mid-cap tech and software, with names like Okta and Lattice Semiconductor doing much of the heavy lifting as their momentum stays firmly in the “rising” camp. Everpure and DocuSign add to the tech tilt, though DocuSign’s more “mixed” and occasionally lagging performance can act like a small brake on returns. Manhattan Associates and Qualys have been steady contributors, while Sterling Infrastructure has seen choppier trading that can tug at near-term results. Overall, this is a U.S.-centric, tech-forward fund powered by cash-rich mid-cap growers.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 DOCU | DocuSign | 4.60% | $51.60K | $15.63B | 18.25% | 71Outperform |
 MEDP | Medpace Holdings | 4.45% | $49.86K | $19.38B | 19.32% | 79Outperform |
 MANH | Manhattan Associates | 4.07% | $45.63K | $13.98B | 28.92% | 75Outperform |
 EXEL | Exelixis | 3.37% | $37.77K | $16.42B | 65.39% | 78Outperform |
 OKTA | Okta | 3.33% | $37.30K | $38.93B | 149.31% | 75Outperform |
 LSCC | Lattice Semiconductor | 3.37% | $37.78K | $14.80B | 45.00% | 71Outperform |
 QLYS | Qualys | 2.74% | $30.77K | $7.73B | 76.01% | 78Outperform |
 FTI | TechnipFMC | 2.43% | $27.20K | $28.00B | 73.55% | 80Outperform |
 JAZZ | Jazz Pharmaceuticals | 2.27% | $25.43K | $13.31B | 48.45% | 64Neutral |
 RMBS | Rambus | 2.43% | $27.21K | $9.75B | -12.23% | 78Outperform |
MCOW Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MCOW, the sentiment is Positive. The current price of 22.45 is above the 20-day moving average (MA) of 22.26, above the 50-day MA of 21.91, and above the 200-day MA of 20.62, indicating a bullish trend. The MACD of 0.15 indicates Negative momentum. The RSI at 57.66 is Neutral, neither overbought nor oversold. The STOCH value of 82.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MCOW.
MCOW Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| MCOW | $22.45 | $24.50(9.15% Upside) | $1.12M | 0.49% | 72Outperform |
 KMID | $24.12 | $28.20(16.92% Upside) | $52.25M | 0.80% | 72Outperform |
 PAMC | $49.58 | $67.20(35.55% Upside) | $49.06M | 0.60% | 68Neutral |
 MMID | $27.16 | $31.63(16.43% Upside) | $36.96M | 0.59% | 68Neutral |
 TMID | $25.75 | $31.00(20.38% Upside) | $12.85M | 0.47% | 67Neutral |
 SMCP | $25.88 | $29.40(13.63% Upside) | $10.32M | 0.79% | 67Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MCOW | Pacer S&P MidCap 400 Quality FCF Aristocrats ETF | 22.45 | 2.37 | 11.79% | |
| KMID | Virtus KAR Mid-Cap ETF | 24.12 | -0.23 | -0.95% | |
| PAMC | Pacer Lunt MidCap Multi-Factor Alternator ETF | 49.58 | 4.44 | 9.84% | |
| MMID | MFS Active Mid Cap ETF | 27.16 | 2.86 | 11.78% | |
| TMID | T. Rowe Price Mid Cap Equity Research ETF | 25.75 | 0.50 | 1.99% | |
| SMCP | SMART Mid Cap ETF | 25.88 | 1.01 | 4.05% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.